<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24577">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786810</url>
  </required_header>
  <id_info>
    <org_study_id>1504311FB</org_study_id>
    <nct_id>NCT02786810</nct_id>
  </id_info>
  <brief_title>Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy</brief_title>
  <official_title>Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be evaluating the efficacy and safety of a contrast drug in pediatric renal
      ultrasound.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visualization of Renal Scars Compared to Previous Imaging</measure>
    <time_frame>1 hour</time_frame>
    <description>The study will evaluate the contrast agent's ability to enable the ultrasound to produce adequate images of the kidneys as compared to the subject's previous renal imaging.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events related to the study drug.</measure>
    <time_frame>1 week</time_frame>
    <description>The study will evaluate how many people experience adverse events, specifically the two most common effects (headache and nausea), during the study or during the week following the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Urinary Tract Infection</condition>
  <condition>Vesicoureteral Reflux</condition>
  <arm_group>
    <arm_group_label>Contrast</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will be recruited into this arm. All subjects will receive 0.03 ml/kg IV sulfur hexafluoride type-a lipid microspheres one time, unless a second, adjusted dose is necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfur hexafluoride type-a lipid microspheres</intervention_name>
    <description>Used as a contrast to enhance renal ultrasound</description>
    <arm_group_label>Contrast</arm_group_label>
    <other_name>LumasonÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age more than or equal to 8 years

          -  Patient with history of urinary tract infection (UTI) and history of Voiding
             Cystourethrogram (VCUG) for vesicoureteral reflux

          -  Candidate for Dimercaptosuccinic acid (DMSA) scan or scan for renal scar

          -  Demonstration of renal scarring by DMSA scan or renal ultrasound without contrast

        Includes healthy volunteers

        Exclusion Criteria:

          -  Age less than 8years

          -  Allergy to contrast or related products

          -  Cardiac shunt/ congenital heart anomalies

          -  Abnormal baseline ECG

          -  Open heart surgery

          -  Evidence of retinopathy

          -  Patient in intensive care

          -  Unable to comply with study requirement

          -  History of emphysema

          -  Unable to maintain oxygen saturation of 92% on at room air

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hains, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Science Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hains, M.D.</last_name>
    <phone>901-287-4876</phone>
    <email>dhains@uthsc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Ellison, R.N.</last_name>
    <phone>901-287-7485</phone>
    <email>eelliso5@uthsc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Ellison, R.N.</last_name>
      <phone>901-287-7485</phone>
      <email>eelliso5@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>David Hains, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 25, 2016</lastchanged_date>
  <firstreceived_date>May 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Vesico-Ureteral Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
